Loading cancer entity…
Loading cancer entity…
Clinical trials
58 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (8)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03076554 | A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy | active not recruiting | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06980077 | Ivonescimab for the Treatment of Thymic Cancer | recruiting | Phase 2 | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07824505 | Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After Chemotherapy | completed | Phase 2 | 74 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06248515 | A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | recruiting | Phase 2 | 18 | Georgetown UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07324629 | Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma | recruiting | Phase 2 | 30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT03463460 | Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer | active not recruiting | Phase 2 | 9 | Dwight OwenOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07750353 | A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas(XANTHOS) | not yet recruiting | Phase 2 | 35 | National Cancer Center, JapanOTHER_GOV | 1 | Aug 6, 2026 | clinicaltrials |
| NCT01025089 | Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma | active not recruiting | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06790706 | IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers(IMMUNORARE5) | active not recruiting | Phase 2 | 27 | Hospices Civils de LyonOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07598955 | Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma(SELECT-NK-THYM) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT03134118 | Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)(NIVOTHYM) | active not recruiting | Phase 2 | 55 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | May 15, 2026 | clinicaltrials |
| NCT06019468 | Neoadjuvant Treatment For Locally Advanced Thymic Cancer | recruiting | Phase 2 | 25 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07479628 | Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma | not yet recruiting | Phase 2 | 31 | Shanghai Chest HospitalOTHER | 0 | Mar 18, 2026 | clinicaltrials |
| NCT04710628 | Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents(PECATI) | completed | Phase 2 | 43 | MedSIROTHER | 3 | Feb 19, 2026 | clinicaltrials |
| NCT06838910 | Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma | recruiting | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT03694002 | Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 21 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 30, 2025 | clinicaltrials |
| NCT03583086 | Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | completed | Phase 1 / Phase 2 | 88 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT01306045 | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | completed | Phase 2 | 647 | National Cancer Institute (NCI)NIH | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04321330 | A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma | completed | Phase 2 | 34 | Hoffmann-La RocheINDUSTRY | 1 | Jun 11, 2024 | clinicaltrials |
| NCT03921671 | Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)(RELEVENT) | unknown | Phase 2 | 60 | Claudia ProtoOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT04925947 | A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors | terminated | Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT04469725 | KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma | terminated | Phase 2 | 95 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT00010257 | Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma | completed | Phase 2 | 46 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy(RESOUND) | completed | Phase 2 | 82 | Istituto Clinico HumanitasOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT03449173 | Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)(Style) | unknown | Phase 2 | 56 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT02364076 | Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma | unknown | Phase 2 | 45 | Georgetown UniversityOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT00198133 | Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma | completed | Phase 2 | 27 | Patrick Joseph Loehrer Sr.OTHER | 1 | Jul 22, 2019 | clinicaltrials |
| NCT01364727 | A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies | completed | Phase 2 | 33 | Heather WakeleeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01011439 | Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma | terminated | Phase 2 | 72 | Tiziana Life Sciences LTDINDUSTRY | 3 | Feb 6, 2019 | clinicaltrials |
| NCT02623127 | A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma(KOSMIC) | completed | Phase 2 | 25 | Seoul National University HospitalOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01100944 | A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies | terminated | Phase 1 / Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Aug 10, 2017 | clinicaltrials |
| NCT00965250 | Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2016 | clinicaltrials |
| NCT00589290 | Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT00818090 | Paclitaxel and Cisplatin for Thymic Neoplasm | terminated | Phase 2 | 39 | Korean Cancer Study GroupOTHER | 1 | Apr 12, 2013 | clinicaltrials |
| NCT00003662 | Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases | completed | Phase 2 | 90 | Roswell Park Cancer InstituteOTHER | 1 | Mar 7, 2011 | clinicaltrials |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials